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Abstract Alterations in mitochondrial metabolism
have been described as one of the major hallmarks of
both ageing cells and cancer. Age is the biggest risk
factor for the development of a significant number of
cancer types and this therefore raises the question of
whether there is a link between age-related mitochon-
drial dysfunction and the advantageous changes in
mitochondrial metabolism prevalent in cancer cells. A
common underlying feature of both ageing and cancer
cells is the presence of somatic mutations of the
mitochondrial genome (mtDNA) which we postulate
may drive compensatory alterations in mitochondrial
metabolism that are advantageous for tumour growth.
In this review, we discuss basic mitochondrial func-
tions, mechanisms of mtDNA mutagenesis and their
metabolic consequences, and review the evidence for
and against a role for mtDNA mutations in cancer
development.
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Mitochondrial function
Mitochondria are present in most eukaryotic cells and
are dynamic, intracellular double-membrane bound
organelles, which function in a variety of roles to
maintain cellular homeostasis. It is thought that the
mitochondrion descended from a free-living a-pro-
teobacterium that formed a symbiotic relationship
within a host cell (Gray 2012; Gray et al. 1999).
During mitochondrial evolution, loss or transfer of the
majority of genes from the a-proteobacterium to the
nuclear genome has occurred (Karlberg et al. 2000).
Subsequently, mitochondria are reliant on the import
of nuclear encoded gene products for biogenesis,
maintenance and function. However, a small
(* 16 kb) circular genome remains known as mito-
chondrial DNA (mtDNA), which is essential for one of
the major functions of mitochondria; adenosine
triphosphate (ATP) synthesis through oxidative phos-
phorylation (OXPHOS). Other important mitochon-
drial functions include iron–sulphur biogenesis and
haem synthesis (Sano et al. 1959), fatty acid synthesis
and oxidation (Hiltunen et al. 2009; Houten and
Wanders 2010), one carbon metabolism (Ducker et al.
2016), regulation of reactive oxygen species (ROS),
(Diebold and Chandel 2016), calcium homeostasis
(Gunter et al. 2000), and induction of apoptosis (Liu
et al. 1996). Below we describe in detail some of the
normal mitochondrial functions that have been shown
to be dysregulated in ageing and cancer (Fig. 1).
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An array of metabolic pathways present within a cell
interconnect to convert stored energy from
carbohydrates, proteins and fats into energy the cell
can utilise in the form of ATP. During glycolysis,
glucose molecules enter a series of chemical reactions
resulting in the reduction of two nicotinamide
Fig. 1 Central carbon metabolic pathways important for
cellular energy production and biosynthetic reactions. In the
cytoplasm, glycolysis can directly lead to the anaerobic
generation of lactate and ATP. Alternatively, in the presence
of oxygen acetyl CoA feeds into the mitochondrial TCA cycle to
generate electron donors for ATP synthesis via OXPHOS.
Depending on the metabolic requirements of the cell, glycolytic
intermediates may be diverted into the pentose phosphate and
serine synthesis pathways. The SSP produces one-carbon units
that supply metabolic pathways such as the mitochondrial and
cytoplasmic folate cycles, purine synthesis, transsulfuration and
the methyl cycle. THF tetrahydrofolate
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adenosine dinucleotide (NAD?) molecules to NADH,
the generation of two ATP molecules and two
pyruvate molecules per glucose molecule. Pyruvate
is transported into the mitochondrion where it is
decarboxylated to acetyl-coenzyme A (acetyl coA) to
allow entry into the tricarboxylic acid (TCA) cycle.
One complete turn through the TCA cycle permits the
phosphorylation of guanosine-50triphoshate (GDP),
reduction of three NAD? molecules to three NADH
molecules and the reduction of one flavin adenine
dinucleotide (FAD) to FADH2 (Cooper 2000).
NADH and FADH2 are both electron donors for
energy generation by OXPHOS (Mitchell 1961). In
this process electrons are transferred from NADH and
FADH2, along the mitochondrial electron transport
chain (ETC), which is composed of protein–lipid
enzyme complexes (I–IV) located in the inner mito-
chondrial membrane (IMM), and is coupled via proton
pumping to the phosphorylation of adenosine diphos-
phate (ADP) to ATP by complex V. Electrons entering
the ETC at complex I are transferred to ubiquinone
(Q), a lipid soluble molecule, which is reduced to
ubiquinol (QH2) and carries the electrons through the
mitochondrial membrane to complex III (cytochrome
c oxido-reductase). Catalysis of electrons transferred
from NADH through complex I to Q, is coupled to the
pumping of four protons into the intermembrane space
(Hinkle et al. 1991). Electrons donated to complex III
from QH2, which is re-oxidised to ubiquinone, are
transferred from cytochrome b in complex III to the
haem protein, cytochrome c, in the peripheral mem-
brane (Hatefi 1985). The catalysis of 2e- by complex
III to cytochrome c is coupled to the translocation of
2H? ions into the intermembrane space (Hinkle et al.
1991). Cytochrome c carries electrons to the final
complex of the ETC complex IV (cytochrome c oxi-
dase), which catalyses the irreversible reduction of O2,
to form H2O (Hatefi 1985). Electrons transferred from
FADH2 to the exclusively nuclear encoded complex II
(succinate dehydrogenase), are passed to Q. Complex
II (also a participant in the TCA cycle) oxidises
succinate to fumarate (Huang and Millar 2013);
however, electrons transferred from FADH2 to
ubiquinone do not release a sufficient amount of free
energy for proton pumping. Only free energy yielded
at complexes I, III and IV is coupled to the translo-
cation of protons from the matrix across the IMM into
the intermembrane space (Hinkle et al. 1991). This
sets up an electrochemical gradient across the
mitochondrial membrane providing a proton motive
force that complex V (ATP synthase) utilizes to
phosphorylate ADP to ATP (Hatefi 1985). Movement
of protons through the membrane embedded cylindri-
cal F0 domain of complex V, drives the rotation of a
central c subunit (Noji et al. 1997). This rotational
motion causes a conformational change of b chains in
the ATP synthase F1 domain of complex V and the
synthesis of ATP from ADP and inorganic phosphate
(Noji et al. 1997).
ROS production
Mitochondria are the major source of cellular ROS
production (Loschen et al. 1971), including superox-
ide, hydrogen peroxide and the hydroxyl radical.
Produced by the reduction of O2 with unpaired
electrons, ROS are highly reactive molecules. A
traditional view of ROS centres on their negative role
in oxidative stress where they cause damage to cellular
proteins, DNA and lipids, and are thought to con-
tribute to disease and ageing (Harman 1956, 1972).
Potential sites of endogenous ROS production include
enzymes with Flavin-containing prosthetic groups
including FAD or Flavin mononucleotide; and
enzymes involved in the TCA cycle, ETC and fatty
acid oxidation. Within the mitochondria the ETC
produces ROS at complexes I and III as by-products
during OXPHOS (Sugioka et al. 1988; Turrens and
Boveris 1980). Delays during the transfer of electrons
down the transport chain facilitates the reaction of
stalled electrons with O2, producing the free radial
superoxide. Furthermore, the strong electrical field
produced by the potential difference between the
matrix and inter-membrane space can cause a diver-
gence of electrons in the IMM along their path. This
electrical field can act as a force, accelerating the
movement of superoxide anions formed within the
IMM towards the inter-membrane space and thus are
more readily accessible to the cytosol (reviewed by
Sabharwal and Schumacker 2014).
Prime targets of oxidative damage are therefore
mitochondrial enzymes, lipids and mtDNA, which lie
in close proximity to the ETC. However mitochondria,
do possess their own antioxidant, mitochondrial
superoxide dismutase, to scavenge high levels of
damaging ROS (McCord and Fridovich 1969; Weisi-
ger and Fridovich 1973). More recently, ROS have
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been shown to participate in signal transduction
oxidation–reduction reactions, primarily oxidising
cysteine residues of a range of target proteins to help
control important physiological processes (Janssen-
Heininger et al. 2008). For example ROS help regulate
responses to growth factor stimulation, metabolic
excess, low oxygen availability, stresses such as
double-stranded DNA breaks, as well as provide
signals to regulate autophagy and the inflammatory
response (Finkel 2011). Thus, mitochondria play a
central role in maintaining homeostasis of ROS levels
that are essential for physiological functioning but at
high levels can be toxic to a cell (reviewed by (Diebold
and Chandel 2016).
Apoptosis
Apoptosis, also referred to as programmed cell death,
is a carefully orchestrated and evolutionarily con-
served mechanism for maintaining a healthy cell
population, protection against genotoxic stress and
pathogen invasion, and the growth and development of
an organism (Wang and Youle 2009). Within a cell
there are two different apoptotic pathways which are
activated by different signals; the intrinsic and the
extrinsic pathway. The extrinsic pathway is dependent
on cell surface death receptors, whereas the intrinsic
pathway is dependent on mitochondrial functioning.
Various studies show a crossover and interaction of
these two pathways (Li et al. 1998; Luo et al. 1998),
with functioning of the mitochondrial dependent
apoptotic pathway being essential (Li et al. 2000).
Dysregulation of the latter pathway has been shown to
lead to abnormal development and disease (Jones et al.
2003; Zhang et al. 2003).
Both pathways involve a cascade of molecular
events with cysteine proteases, termed caspases that
controllably leads a cell to self-destruct. Controlling
this process are a large family of B cell lymphoma
(Bcl-2) protein homologs, which comprise anti- and
pro-apoptotic proteins (Cory and Adams 2002).
Additionally, a further group of heterogeneous pro-
teins, the BH3 family, which act as pro-apoptotic
proteins by interacting with and inhibiting the anti-
apoptotic Bcl-2 proteins (Youle and Strasser 2008).
Focusing on the mitochondrial apoptotic pathway,
induction is shown to occur in response to stress
including DNA damage, oxidative damage, starvation,
serum starvation, chemotherapeutic agents and excess
Ca2? (Sattler and Tymianski 2000; Wang and Youle
2009). Such apoptotic stimuli causes Bax and Bak,
which under normal conditions shuttle between the
cytosol and the outer mitochondrial membrane
(OMM), to change conformation and oligomerise in
the OMM (Griffiths et al. 1999; Hsu et al. 1997;
Wolter et al. 1997). This enables permeabilization of
the mitochondrial membrane for release of apoptotic
proteins, including cytochrome c, which in turn is
essential for activating the caspase cascade for
programmed cell death to occur (Liu et al. 1996;
Lovell et al. 2008; Wang and Youle 2009).
One carbon metabolism
One-carbon metabolism comprises a network of
biosynthetic reactions that occur in the cytoplasm
and mitochondria to provide one-carbon units as the
building blocks for cellular biosynthesis, methylation
and redox reactions (reviewed by Rosenzweig et al.
2018). The one-carbon units are derived from different
nutrients, largely the non-essential amino acids serine
and glycine (Kalhan and Hanson 2012), which can
then flow into the folate cycle and the methionine
cycle. Serine and glycine can be sourced exogenously
or generated de novo from glucose along a series of
enzymatic reactions collectively referred to as the
serine synthesis pathway (SSP) (Locasale et al. 2011).
The folate cycle can occur in the cytoplasm but occurs
more favourably in the mitochondrion (Ducker et al.
2016) with each compartment having their own
enzymatic machinery.
The folate cycle first reduces folic acid to tetrahy-
drofolate (THF), the biologically active form (New-
man and Maddocks 2017). THF can then be
methylated by serine hydroxymethyltransferase
(SHMT) or glycine decarboxylase (GDLC), into
methyl-THF in the presence of serine or glycine
respectively. Methyl-THF then undergoes a series of
redox reactions catalysed by the mitochondrial or
cytoplasmic isoforms of methylenetetrahydrofolate
dehydrogenase (MTHFD1/2/1L). Notably, a consid-
erable amount of reduced nicotinamide adenine din-
ucleotide phosphate (NADPH) production, equal to
that of the pentose phosphate pathway occurs by the
mitochondrial folate pathway (Fan et al. 2014). The
generation of formate through this pathway can then
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feed into purine synthesis or alternatively methyl-THF
may enter into the methionine cycle, important for
epigenetic modifications, and methylation reactions
(Finkelstein 1990) (Fig. 1).
In the methionine cycle methylation of homocys-
teine by methyl-THF, forms the only essential sul-
phur-containing amino acid, methionine (Finkelstein
2000). Moreover generation of ATP during the folate
cycle can then be used in the methionine cycle to
synthesise S-adenosyl-methionine (SAM) by reacting
with methionine (Markham et al. 1980); SAM is the
major universal methyl-donor in living organisms
(Chiang et al. 1996). Amongst a broad range of
methylation reactions required for cellular function-
ing, there is a high demand for mitochondrial
10-formyl-THF which is required for the formylation
of the initiator methionine tRNA for protein transla-
tion in the mitochondria (Tucker et al. 2011). To
complete the cycle homocysteine can also be regen-
erated by the demethylation of SAM. Of note homo-
cysteine can also branch off into the transsulfuration
pathway for the generation of the antioxidant glu-
tathione (Zhou et al. 2017). Thus, mitochondria
support one-carbon redistribution essential for purine,
ATP, NADP and glutathione synthesis and methyla-
tion reactions, which are crucial for controlling cell
fate and homeostasis.
Mitochondrial genetics
The majority of mammalian somatic cells contain
many mitochondria. mtDNA copy number is thought
to reach 103–104 per cell (Lightowlers et al. 1997),
with mature oocytes containing at least 105 copies
(Shoubridge and Wai 2007). mtDNA contains 37
genes, which encode 13 protein subunits of the
mitochondrial ETC, the mitochondrial translation
machinery, in the form of a 12S and 16S ribosomal
RNA (rRNA), and a full complement of 22 transfer
RNAs (tRNAs). The mitochondrial genome has a
unique genetic code (Barrell et al. 1979) with an
extremely economical organisation, lacking introns,
and only having a few noncoding bases between some
genes (Anderson et al. 1981). The only exception to
this being the displacement loop (D-loop) region,
which contains the three promoter regions of the H-
and L-strand (Kasamatsu et al. 1971). Moreover, there
is overlap of some protein encoding genes e.g. ND4
and ND4L, and the transcription termination codon for
many mRNAs is not encoded but is instead generated
by post-transcriptional polyadenylation (Anderson
et al. 1981; Ojala et al. 1981).
mtDNA lacks histones and is packaged into nucle-
oprotein complexes called nucleoids, containing sin-
gle or multiple mtDNAmolecules (Bogenhagen 2012;
Satoh and Kuroiwa 1991). The most abundant protein
responsible for co-operatively binding and wrapping
mtDNA to form these compact segregated units is the
HMG-box protein, mitochondrial transcription factor
A (TFAM) (Kaufman et al. 2007; Parisi and Clayton
1991). However, other nucleoid core proteins which,
like TFAM, also play roles in mtDNA replication and
transcription include the mitochondrial DNA poly-
merase c (POLc), mitochondrial RNA polymerase
(POLRMT), mitochondrial single-strand binding pro-
tein (mtSSB) and the mitochondrial TWINKLE heli-
case (Bogenhagen et al. 2008). Towards the periphery
of nucleoids other proteins involved in translation and
complex assembly and those in the IMM e.g. pro-
hibitin, are present, associating the mtDNA with the
IMM (Bogenhagen et al. 2008; Falkenberg et al.
2007).
The multi-copy nature of mtDNA means that cells
rarely exist in a state where all copies are identical
(homoplasmy), in fact, the vast majority of cells
contain a mixture of wild-type (WT) and mutated
molecules, termed heteroplasmy (Stewart and Chin-
nery 2015; Taylor and Turnbull 2005). However, the
high copy number and highly recessive nature of
mtDNA mutations within a cell allows WT mtDNA to
compensate for mutated mtDNA up to a certain point
(Sciacco et al. 1994). Beyond a critical threshold
however, a biochemical defect occurs. The threshold
level is dependent on the tissue type, and it’s metabolic
demand (Rossignol et al. 1999), as well as the number
of residual WT mtDNA copies (Sciacco et al. 1994).
mtDNA mutations and mitochondrial dysfunction
in ageing tissues
The mt.8344A[G transition in the tRNALys gene,
and mt.3243A[G transition in the tRNALeu gene,
were the first mtDNA point mutations detected to be
present at higher levels in homogenate ageing tissues
such as brain, heart, liver, kidney and skeletal muscle
(Mu¨nscher et al. 1993; Zhang et al. 1993). Nekhaeva
123
Biogerontology
et al. then used single-cell sequence analysis and
showed that a subset of normal ageing buccal epithe-
lial cells and cardiomyocytes contain mtDNA muta-
tions at high levels of heteroplasmy or homoplasmy
(Nekhaeva et al. 2002). Since this discovery, an age-
related increase in the frequency of cells with high
level mtDNA point mutations resulting in OXPHOS
defects have been detected in a number of ageing
mitotic tissues such as colon, stomach, small intestine,
oesophagus and liver (Fellous et al. 2009b; Greaves
et al. 2010; McDonald et al. 2008; Taylor et al. 2003).
mtDNA point mutations in ageing tissues appear to
occur at random throughout the mitochondrial gen-
ome; however, the mechanism underlying their gen-
eration has been an area of much debate. The
mitochondrial theory of ageing postulates that due to
its close proximity to the mitochondrial respiratory
chain, the mtDNA is highly susceptible to oxidative
damage (Miquel et al. 1980). This can result in base
modifications, sugar damage, strand breaks and abasic
sites (Wang et al. 1998). Commonly produced base
lesions are 7,8-dihydro-8-oxo-20-deoxyguanoisine (8-
oxo-dG) (Bohr 2002) and thymine glycols (Wang et al.
1998). The formation of 8-oxod-G is suggested to
induce G:T transversions by POLc, whereas thymine
glycols are thought to be less mutagenic and instead
block polymerisation (Alexeyev et al. 2013; Hanes
et al. 2006). Analysis of mutational spectra from aged
mitotic and post-mitotic human tissues has shown that
the pattern is not consistent with the G:C to T:A
transversions caused by oxidative damage (Greaves
et al. 2014; Kennedy et al. 2013), but instead, the most
common mutation type were G:C to A:T transitions.
These are more likely caused by errors during mtDNA
replication and/or spontaneous cytosine deamination
(Zheng et al. 2006). Along with multiple studies of
mtDNA mutational spectra in transgenic mouse mod-
els (reviewed by Kauppila et al. 2017), these data
suggest a limited role for ROS in age-related mtDNA
point mutation generation.
Within ageing mitotic cells, mtDNA point muta-
tions are commonly present at high levels of hetero-
plasmy or homoplasmy. How one mutated mtDNA
molecule clonally expands to become the dominant
species within a cell, resulting in a biochemical defect,
has been debated for a number of years without a
definitive mechanism being agreed upon. In 1997 de
Grey suggested that individual cells with mutated
mtDNA and subsequent respiratory chain deficiency
would result in the production of fewer ROS, resulting
in lower levels of mitochondrial membrane damage.
Mitochondria with WT mtDNA and with normal
respiratory chain function would produce more ROS
and suffer a higher rate of oxidative membrane
damage, and thus more likely be targeted for lysoso-
mal degradation. Mitochondria with mutated mtDNA
would therefore have a selective survival advantage
and rapidly populate the cell (de Grey 1997). How-
ever, this ‘survival of the slowest’ hypothesis (Kowald
and Kirkwood 2000), only explains clonal expansion
after a respiratory deficiency has been reached and
does not acknowledge the dynamic reticular network
of mitochondria. Computational simulations have
suggested that simple genetic drift is able to explain
the clonal expansion of mtDNA mutations in mitotic
cell populations (Coller et al. 2001; Stamp et al. 2018).
These models suggest that the initial mutational events
occur early in life, then through successive cycles of
mtDNA replication followed by random segregation at
cell division, mutations are either lost or can expand to
become the dominant species within the cell, resulting
in mitochondrial dysfunction. Additionally, as the
stem cells of mitotic tissues are the most-long lived
cell types, once a mtDNA mutation becomes fixed
within a stem cell, this will be transmitted to all of the
stem cell progeny. This results in the patches of cells
with OXPHOS defects that have been documented in
ageing stem-cell derived populations (Fellous et al.
2009a; McDonald et al. 2008; Stamp et al. 2018).
In addition to the most commonly documented
consequences of mtDNA mutations, which are defects
in OXPHOS, a number of groups have investigated the
downstream consequences of OXPHOS dysfunction
on other aspects of mitochondrial metabolism. Nikka-
nen et al. analysed skeletal muscle from a mouse
model of progressive mtDNAmutagenesis caused by a
mutation in the TWINKLE gene. They detected an
upregulation of the mitochondrial folate cycle and
purine synthesis and increased glucose uptake for de
novo serine and glutathione synthesis in response to
mitochondrial stress (Nikkanen et al. 2016), which
was subsequently shown to be controlled via the
mechanistic (mammalian) target of rapamycin
(mTOR) complex I (mTORC1) pathway (Khan et al.
2017). These pathways were also confirmed to be
upregulated in blood and muscle of patients with
mitochondrial diseases (Buzkova et al. 2018). Folate-
driven one carbon metabolism is the major anabolic
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biosynthesis pathway, which provides one-carbon
units for cell growth and repair. Bao et al. showed
that a number of genes in the de novo SSP were
regulated at the transcriptional level by the transcrip-
tion factor ATF4, and ATF4 mediated rewiring of
mitochondrial one-carbon metabolism following
ethidium bromide mediated depletion of mtDNA in
cell lines (Bao et al. 2016). These data show that cells
with mitochondrial dysfunction are able to rewire their
metabolism in an attempt to maintain cellular
homeostasis.
Despite the plethora of evidence showing an
association of mtDNA mutations with human ageing,
it is still not clear whether these are a cause or
consequence of ageing. The mitochondrial mutator
mouse model was developed to address this directly.
The mutator mouse harbours an error prone mito-
chondrial polymerase gamma, which causes the
accumulation of mtDNA mutations systemically with
age (Kujoth et al. 2005; Trifunovic et al. 2004). This
results in a premature ageing phenotype with greying
of hair, kyphosis, reduced subcutaneous fat, osteo-
porosis, reduced fertility, anaemia and heart enlarge-
ment leading to a reduced lifespan (\ 12 months). A
number of other groups have used the mutator mouse
model to investigate how mitochondrial dysfunction
may specifically contribute to ageing processes in
specific cell and tissues types. These studies have
shown defects in innate immunity regulation (Niu
et al. 2007), inflammation (Logan et al. 2014), stem
cell activity (Ahlqvist Kati et al. 2012; Chen et al.
2009) and levels of apoptosis (Norddahl Gudmundur
et al. 2011). Taken together these studies suggest that,
in this model, mitochondrial dysfunction can drive
ageing through a combination of perturbations in ROS
signalling pathways and defects in cellular bioener-
getics (Baines et al. 2014).
Mitochondrial dysfunction in cancer
Altered mitochondrial metabolism in cancer cells
Mitochondrial function was first proposed to play a
role in cancer biology in the early twentieth century.
Cancer cells exhibiting rapid growth and proliferation
rates in harsh tumour microenvironments, must adapt
their metabolism to meet the high energy demands
required for these processes. Warburg first
documented tumours undergoing a metabolic switch
with increased levels of glucose uptake and a high rate
of glycolysis, even in the presence of oxygen (War-
burg 1913, 1956a, b; Warburg et al. 1927). This
property of tumour cells, termed the ‘Warburg effect’,
is still utilised in clinical monitoring of oncology
patients by positron-emission tomography (PET),
which allows detection of high glucose uptake by
primary and metastatic tumours (Di Chiro et al. 1982;
Hawkins and Phelps 1988). There is a positive
correlation between tumour aggressiveness and glu-
cose uptake (Kunkel et al. 2003). Energy derivation
via glycolysis may be seen as a disadvantage, yielding
only two ATP molecules per glucose molecule instead
of 36 ATP molecules through complete aerobic
oxidation. However, switching from mitochondrial
OXPHOS to aerobic glycolysis may permit adaptation
to the hypoxic tumour microenvironment. ATP gen-
eration by glycolysis can occur at a faster rate than
OXPHOS (Pfeiffer et al. 2001) and diversion of
pyruvate away from OXPHOS to lactate production
and anabolic processes such as the pentose phosphate
pathway for nucleotide, lipid and amino acid gener-
ation, may aid rapid proliferation (Giampazolias and
Tait 2016).
Currently there is still much support for the
Warburg Effect in tumours. Warburg, however, pro-
posed aerobic glycolysis was in fact due to a defect in
mitochondria (Warburg 1956b), suggesting mitochon-
dria were dispensable for the oncogenic process.
However, the recognition of mitochondrial outer
membrane permeabilisation as a critical point in
programmed cell death (Zamzami et al. 1995) and
earlier reports of the mitochondrial membrane poten-
tial being higher in cancer cells (Chen 1988), impli-
cated the dysfunctional control of mitochondria to be
crucial for the evasion of apoptosis by cancer cells
(Hanahan and Weinberg 2000). A significant involve-
ment and dependence of mitochondrial functioning in
malignant transformation and tumour progression as
well as the influence in response to anticancer
treatments has become apparent (Porporato et al.
2017). Subsequently, a vast range of studies have
appealed for aberrant functioning of mitochondria to
be investigated as potential targets for the develop-
ment of cancer therapies (Fulda et al. 2010; Pustyl-
nikov et al. 2018). Drugs that target mitochondria to
re-sensitise cells to apoptosis for example, have been
clinically approved for use in treatment e.g.
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venetoclax for chronic lymphocytic leukemia (Ashke-
nazi et al. 2017; Sarosiek and Letai 2016).
Metabolic rewiring in tumours is not limited to
increases in glucose uptake for ATP synthesis by
glycolysis, or upregulation of the pentose phosphate
pathway. The harsh and constantly evolving tumour
microenvironment requires other metabolic circuits
and entries between mitochondrial and cytoplasmic
compartments to be suitably co-ordinated and selected
for tumour survival. For example, increased glutamine
consumption and metabolism feeds into the TCA
cycle for ATP synthesis, fatty acid and nucleotide
synthesis, is seen in tumours and has been explored as
therapeutic channel (Altman et al. 2016). Addition-
ally, cancer cells are shown to recruit and utilise other
carbon sources such as acetate, glycine and serine to
adapt to and support their growth and proliferation in
the tumour microenvironment (Maddocks et al. 2013;
Mashimo et al. 2014). The heterogeneity of conditions
such as oxygenation, within a tumour has also been
shown to set up a variation in metabolic profiles and
symbiosis between tumour regions for the exchange of
metabolites. Tumour regions under hypoxia utilising
glucose for glycolysis and releasing lactic acid, are
shown to fuel oxidative tumour cells, thus sparing
glucose for neighbouring hypoxic tumour regions
(Feron 2009; Sonveaux et al. 2008).
Nuclear DNA mutations in metabolism genes
in cancer
The rewiring and plasticity of mitochondrial metabo-
lism and signalling in aiding tumourigenesis has been
highlighted from the gene level up to the protein and
functional level. At the genetic level tumours have
been reported to harbour mutations in nuclear encoded
enzymes involved in metabolism and accumulate
associated oncometabolites, thought to increase
tumorigenesis. In numerous types of tumours, muta-
tions and changes in activity of TCA cycle enzymes
have been detected including citrate synthase, aconi-
tase (Schlichtholz et al. 2005; Singh et al. 2006),
fumarate hydratase (Tomlinson et al. 2002), succinate
dehydrogenase (Bardella et al. 2011) and isocitrate
dehydrogenase (Balss et al. 2008). However, depend-
ing on the anatomical location of the tumour, some of
these genes can be found to be either upregulated or
downregulated, and induce different oncogenic pro-
cesses. Mutations of isocitrate dehydrogenase for
example are frequently found in brain tumours (Balss
et al. 2008), and are suggested to raise 2-hydroxyg-
lutarate levels (Dang et al. 2009), to help drive
oncogenic promoting processes through DNA hyper-
methylation (Figueroa et al. 2010) and histone mod-
ification (Lu et al. 2012). Moreover, in cervical
carcinoma cell lines mutations in citrate synthase are
reported to cause downregulation in support of a
glycolytic switch (Lin et al. 2012). On the other hand
upregulation of citrate in pancreatic cancer has been
hypothesised to favour synthesis of fatty acids (Sch-
lichtholz et al. 2005), which fuels pancreatic tumour
progression (Blum and Kloog 2014; Witkiewicz et al.
2008). The heterogeneity between tumour types and
requirements is therefore extremely variable, and a
generic role for these enzymes in cancer is somewhat
debatable.
mtDNA mutations in cancer cells
The detection of somatic mutations in the mtDNA of
tumours has been documented in a range of cancers,
such as colon, breast, liver and lung cancers (Chatter-
jee et al. 2006). Moreover the importance of mtDNA
mutations in the metabolic rewiring and functioning of
cancer cells is amplified by a loss of tumourigenicity
by brain and breast cancer cells after the depletion of
mtDNA (Cavalli et al. 1997; Weinberg et al. 2010).
Comprising most protein subunits and the largest of all
respiratory chain complexes, mtDNA mutations in
complex I are the most commonly reported in tumours
(reviewed by Gaude and Frezza 2014). Mutations in
complex I mtDNA genes have been suggested to be
required for a glycolytic switch (Calabrese et al. 2013)
and ROS-driven metastasis (He et al. 2013; Ishikawa
et al. 2008) by cancer cells. However, there appears to
be a diverse tumorigenic potential of different mtDNA
mutations affecting complex I activity with severe
deficiency reducing tumorigenesis in osteosarcoma
cells in vitro and in vivo (Iommarini et al. 2014).
Mutations in mtDNA encoding genes of complexes III
(Dasgupta et al. 2009), IV and V are also thought to
influence tumourigenesis. Mutations in Complex III
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are reported to increase cancer cell growth through an
increase in ROS production and apoptotic resistance
(Dasgupta et al. 2009).
There are contrasting reports on the role of mtDNA
and nuclear DNA encoded complex IV subunits in
cancer progression. An upregulation of nuclear
encoded subunits of complex IV have been detected
in leukaemia cells which increases cellular OXPHOS
and exacerbates ROS production (Chen and Pervaiz
2009), whereas mutations of mtDNA encoded com-
plex IV subunits which decrease OXPHOS and
increase ROS production have been detected in
prostate cancer and ovarian tumours (Petros et al.
2005). This suggests a bias towards oncogenic
promotion by nuclear encoded complex IV subunits,
with mtDNA encoded complex IV subunit activity
supressing tumour growth (Gaude and Frezza 2014).
Complex V is the final enzyme of the OXPHOS
system and forms part of the permeability transition
pore for calcium flux and apoptosis. Mutations in
complex V have been suggested to cause apoptotic
resistance, promoting cancer cell survival (Shidara
et al. 2005). An elegant study by Gaude et al.
engineered a cytoplasmic hybrid (cybrid) cell line
with various heteroplasmy levels of the m.8993 T[G
mutation in MT-ATP6, termed mTUNE lines. They
showed that at high levels of heteroplasmy mTUNE
cells made a glycolytic switch that was coupled by
malate dehydrogenase 1 to reductive carboxylation of
glutamine—a process that drives cell proliferation and
migration. This switch was lost when the hetero-
plasmy level of the m.8993T[G mutations was low
(Gaude et al. 2018). These data provide evidence that
high-level heteroplasmic mtDNA mutations can pro-
mote an oncogenic metabolic phenotype. Other evi-
dence suggesting that mtDNA mutations can promote
a pro-oncogenic metabolic phenotype is the observed
upregulation of de novo serine synthesis and one
carbon metabolism that has been shown to occur in
both cell lines with mtDNA mutations or depletion
(Bao et al. 2016), and in animal models of mitochon-
drial myopathy (Khan et al. 2017; Nikkanen et al.
2016). Upregulation of these pathways has also been
shown to promote cancer cell growth in animal models
of intestinal cancer and lymphoma (Maddocks et al.
2017).
Alongside tumour growth and proliferation, the
multi-step process of metastatic disease development
also requires certain aspects of mitochondrial func-
tioning. Metastasis first involves the epithelial to
mesenchymal transition of cancer cells to allow
migration (Nieto et al. 2016). The invasive potential
of cancer cells during this transition is suggested to be
supported and manipulated by mitochondrial biogen-
esis, OXPHOS and dynamics (Caino et al. 2016;
LeBleu et al. 2014), as well as mitochondrial metabo-
lites such as fumarate (Sciacovelli et al. 2016).
Moreover, assays in mice showed high metastatic
potential of cells with mutations in MT-ND6 of
complex I, linking metastasis with the overproduction
of ROS (Ishikawa et al. 2008). Other studies have
further identified metastatic dissemination to be pro-
moted by mitochondrial ROS overproduction and
associated signal transduction cascades (Comito et al.
2011; Porporato et al. 2014). Protection of cancer cells
against ROS is partially due to increased glucose flux
through the pentose phosphate pathway leading to
antioxidant production, thus promoting their survival
(Schafer et al. 2009). However, beyond a certain
threshold, levels of ROS may inhibit metastasis
(Piskounova et al. 2015). A recent study has shown
that during metastasis, detachment of the tumour cells
from the extracellular matrix followed by dissemina-
tion through the circulation is a rate limiting step in the
process. This process is enhanced by reduced mito-
chondrial capacity and a reliance on glycolysis for
ATP production which is supported by reductive
carboxylation of glutamine; if this is prevented there is
induction of ROS production and cell death, and
inhibition of metastatic spread (Labuschagne et al.
2019).
Conclusions
Metabolic rewiring is an important feature of many
cancer types with metabolism moved away from
OXPHOS towards anabolic pathways, providing
biosynthetic building blocks for cell proliferation
andmigration.Mutations of the mtDNA are frequently
observed in a number of solid tumour types (Ju et al.
2014; Salas et al. 2005) and are very common in
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normal ageing mitotic tissues. Importantly, non-
cancer cells with OXPHOS defects due to mtDNA
mutations upregulate some of the same metabolic
pathways as those upregulated in cancers; posing an
interesting question as to whether ageing cells with
mtDNA mutations provide a favourable metabolic
environment for tumour growth following transfor-
mation. Alternatively, as mtDNA mutations clonally
expand rapidly in proliferating cells, this may occur
during the tumour development, generating subsets of
cell clones with a more favourable metabolic profile
that out-compete other clones and promote tumour
progression and metastasis (Fig. 2). Whether mtDNA
mutations are drivers or passengers in the oncogenic
process is still a matter of debate. It is likely that they
will have differential effects depending on the tissue of
origin and the specific mtDNA mutation present. In
addition, further research sub-classifying tumours into
those with and without mtDNA mutations and the
effect of those mutations on tumour cell metabolism,
may help to elucidate the functional effects of such
mutations in the tumorigenic process, and whether
mtDNAmutations cause metabolic vulnerabilities that
may be exploited therapeutically.
Fig. 2 Schematic to show the hypothesised mechanisms by
which mitochondrial DNA mutations may become manifest in
tumours and either inhibit or promote tumour growth and/or
progression. WT mtDNA is depicted in blue. Mutated mtDNA
molecules conferring an advantageous metabolic phenotype for
tumour growth are shown in green, and those causing a
detrimental metabolic phenotype are shown in red
123
Biogerontology
Acknowledgements This work was funded by the Newcastle
University Centre for Aging and Vitality supported by the
BBSRC, EPSRC, ESRC, and MRC (Grant No: MR/L016354/1)
as part of the cross-council Lifelong Health and Wellbeing
Initiative; the Wellcome Centre for Mitochondrial Research
(Grant No: 203105/z/16/z) and the Barbour Foundation. We
thankMiss Anna Smith and Dr Amy Reeve for critical review of
the manuscript.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrest-
ricted use, distribution, and reproduction in any medium, pro-
vided you give appropriate credit to the original author(s) and
the source, provide a link to the Creative Commons license, and
indicate if changes were made.
References
Ahlqvist Kati J et al (2012) Somatic progenitor cell vulnerability
to mitochondrial DNA mutagenesis underlies progeroid
phenotypes in polg mutator mice. Cell Metab 15:100–109
Alexeyev M, Shokolenko I, Wilson G, LeDoux S (2013) The
maintenance of mitochondrial DNA integrity–critical
analysis and update. Cold Spring Harb Perspect Biol
5:a012641
Altman BJ, Stine ZE, Dang CV (2016) From Krebs to clinic:
glutamine metabolism to cancer therapy. Nat Rev Cancer
16:619
Anderson S et al (1981) Sequence and organization of the
human mitochondrial genome. Nature 290:457–465
Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ (2017)
From basic apoptosis discoveries to advanced selective
BCL-2 family inhibitors. Nat Rev Drug Discov 16:273
Baines HL, Turnbull DM, Greaves LC (2014) Human stem cell
aging: do mitochondrial DNA mutations have a causal
role? Aging Cell 13:201–205
Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von
Deimling A (2008) Analysis of the IDH1 codon 132
mutation in brain tumors. Acta Neuropathol 116:597–602
Bao XR et al (2016) Mitochondrial dysfunction remodels one-
carbon metabolism in human cells. Elife 5:e10575
Bardella C, Pollard PJ, Tomlinson I (2011) SDH mutations in
cancer. Biochim Biophys Acta (BBA)-Bioenergetics
1807:1432–1443
Barrell BG, Bankier AT, Drouin J (1979) A different genetic
code in human mitochondria. Nature 282:189–194
Blum R, Kloog Y (2014) Metabolism addiction in pancreatic
cancer. Cell Death Dis 5:e1065
Bogenhagen DF (2012) Mitochondrial DNA nucleoid structure.
Biochim Biophys Acta 1819:914–920
Bogenhagen DF, Rousseau D, Burke S (2008) The layered
structure of human mitochondrial DNA nucleoids. J Biol
Chem 283:3665–3675
Bohr VA (2002) Repair of oxidative DNA damage in nuclear
and mitochondrial DNA, and some changes with aging in
mammalian cells. Free Radic Biol Med 32:804–812
Buzkova J et al (2018) Metabolomes of mitochondrial diseases
and inclusion body myositis patients: treatment targets and
biomarkers. EMBO Mol Med 10:e9091
Caino MC et al (2016) A neuronal network of mitochondrial
dynamics regulates metastasis. Nat Commun 7:13730
Calabrese C et al (2013) Respiratory complex I is essential to
induce a Warburg profile in mitochondria-defective tumor
cells. Cancer Metab 1:11
Cavalli LR, Varella-Garcia M, Liang BC (1997) Diminished
tumorigenic phenotype after depletion of mitochondrial
DNA. Cell Growth Differ 8:1189–1198
Chatterjee A, Mambo E, Sidransky D (2006) Mitochondrial
DNAmutations in human cancer. Oncogene 25:4663–4674
Chen LB (1988) Mitochondrial membrane potential in living
cells. Annu Rev Cell Biol 4:155–181
Chen ZX, Pervaiz S (2009) Involvement of cytochrome c oxi-
dase subunits Va and Vb in the regulation of cancer cell
metabolism by Bcl-2. Cell Death Differ 17:408
Chen ML et al (2009) Erythroid dysplasia, megaloblastic ane-
mia, and impaired lymphopoiesis arising from mitochon-
drial dysfunction. Blood 114:4045–4053
Chiang PK, Gordon RK, Tal J, Zeng GC, Doctor BP, Pard-
hasaradhi K, McCann PP (1996) S-Adenosylmethionine
and methylation. FASEB J 10:471–480
Coller HA, Khrapko K, Bodyak ND, Nekhaeva E, Herrero-
Jimenez P, Thilly WG (2001) High frequency of homo-
plasmic mitochondrial DNA mutations in human tumors
can be explained without selection. Nat Genet 28:147–150
Comito G et al (2011) HIF-1a stabilization by mitochondrial
ROS promotes Met-dependent invasive growth and vas-
culogenic mimicry in melanoma cells. Free Radic Biol
Med 51:893–904
Cooper G (2000) The cell: a molecular approach, 2nd edn.
Sinauer Associates, Sunderland
Cory S, Adams JM (2002) The Bcl2 family: regulators of the
cellular life-or-death switch. Nat Rev Cancer 2:647–656
Dang L et al (2009) Cancer-associated IDH1 mutations produce
2-hydroxyglutarate. Nature 462:739–744
Dasgupta S, Hoque MO, Upadhyay S, Sidransky D (2009)
Forced cytochrome B gene mutation expression induces
mitochondrial proliferation and prevents apoptosis in
human uroepithelial SV-HUC-1 cells. Int J Cancer
125:2829–2835
de Grey AD (1997) A proposed refinement of the mitochondrial
free radical theory of aging. Bioessays 19:161–166
Di Chiro G et al (1982) Glucose utilization of cerebral gliomas
measured by [18F] fluorodeoxyglucose and positron
emission tomography. Neurology 32:1323–1329
Diebold L, Chandel NS (2016)Mitochondrial ROS regulation of
proliferating cells. Free Radic Biol Med 100:86–93
Ducker GS et al (2016) Reversal of cytosolic one-carbon flux
compensates for loss of the mitochondrial folate pathway.
Cell Metab 23:1140–1153
Falkenberg M, Larsson N-G, Gustafsson CM (2007) DNA
replication and transcription in mammalian mitochondria.
Annu Rev Biochem 76:679–699
Fan J, Ye J, Kamphorst JJ, Shlomi T, Thompson CB, Rabi-
nowitz JD (2014) Quantitative flux analysis reveals folate-
dependent NADPH production. Nature 510:298–302
123
Biogerontology
Fellous TG et al (2009a) Locating the stem cell niche and tracing
hepatocyte lineages in human liver. Hepatology
49:1655–1663
Fellous TG et al (2009b) A methodological approach to tracing
cell lineage in human epithelial tissues. Stem Cells
27:1410–1420
Feron O (2009) Pyruvate into lactate and back: from the War-
burg effect to symbiotic energy fuel exchange in cancer
cells. Radiother Oncol 92:329–333
Figueroa ME et al (2010) Leukemic IDH1 and IDH2 mutations
result in a hypermethylation phenotype, disrupt TET2
function, and impair hematopoietic differentiation. Cancer
Cell 18:553–567
Finkel T (2011) Signal transduction by reactive oxygen species.
J Cell Biol 194:7–15
Finkelstein JD (1990) Methionine metabolism in mammals.
J Nutr Biochem 1:228–237
Finkelstein JAMESD (2000) Pathways and regulation of
homocysteine metabolism in mammals. Semin Thromb
Hemost 26:219–226
Fulda S, Galluzzi L, Kroemer G (2010) Targeting mitochondria
for cancer therapy. Nat Rev Drug Discov 9:447
Gaude E, Frezza C (2014) Defects in mitochondrial metabolism
and cancer. Cancer Metab 2:10
Gaude E et al (2018) NADH shuttling couples cytosolic
reductive carboxylation of glutamine with glycolysis in
cells with mitochondrial dysfunction. Mol Cell
69(581–593):e587
Giampazolias E, Tait SW (2016) Mitochondria and the hall-
marks of cancer. FEBS J 283:803–814
Gray MW (2012) Mitochondrial Evolution. Cold Spring Harb
Perspect Biol 4:a011403
Gray MW, Burger G, Lang BF (1999) Mitochondrial evolution.
Science 283:1476–1481
Greaves LC, Barron MJ, Plusa S, Kirkwood TB, Mathers JC,
Taylor RW, Turnbull DM (2010) Defects in multiple
complexes of the respiratory chain are present in ageing
human colonic crypts. Exp Gerontol 45:573–579
Greaves LC et al (2014) Clonal expansion of early to mid-life
mitochondrial DNA point mutations drives mitochondrial
dysfunction during human ageing. PLoS Genet
10:e1004620
Griffiths GJ et al (1999) Cell damage-induced conformational
changes of the pro-apoptotic protein Bak in vivo precede
the onset of apoptosis. J Cell Biol 144:903–914
Gunter TE, Buntinas L, Sparagna G, Eliseev R, Gunter K (2000)
Mitochondrial calcium transport: mechanisms and func-
tions. Cell Calcium 28:285–296
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell
100:57–70
Hanes JW, Thal DM, Johnson KA (2006) Incorporation and
replication of 8-oxo-deoxyguanosine by the human mito-
chondrial DNA polymerase. J Biol Chem
281:36241–36248
Harman D (1956) Aging: a theory based on free radical and
radiation chemistry. J Gerontol 11:298–300
Harman D (1972) The biologic clock: the mitochondria? J Am
Geriatr Soc 20:145–147
Hatefi Y (1985) The mitochondrial electron transport and
oxidative phosphorylation system. Annu Rev Biochem
54:1015–1069
Hawkins RA, Phelps ME (1988) PET in clinical oncology.
Cancer Metastasis Rev 7:119–142
He X et al (2013) Suppression of mitochondrial complex I
influences cell metastatic properties. PLoS ONE 8:e61677
Hiltunen JK, Schonauer MS, Autio KJ, Mittelmeier TM, Kas-
taniotis AJ, Dieckmann CL (2009)Mitochondrial fatty acid
synthesis type II: more than just fatty acids. J Biol Chem
284:9011–9015
Hinkle PC, Kumar MA, Resetar A, Harris DL (1991) Mecha-
nistic stoichiometry of mitochondrial oxidative phospho-
rylation. Biochemistry 30:3576–3582
Houten SM, Wanders RJA (2010) A general introduction to the
biochemistry of mitochondrial fatty acid b-oxidation. J In-
herit Metab Dis 33:469–477
Hsu YT, Wolter KG, Youle RJ (1997) Cytosol-to-membrane
redistribution of Bax and Bcl-X(L) during apoptosis. Proc
Natl Acad Sci USA 94:3668–3672
Huang S, Millar AH (2013) Succinate dehydrogenase: the
complex roles of a simple enzyme. Curr Opin Plant Biol
16:344–349
Iommarini L et al (2014) Different mtDNA mutations modify
tumor progression in dependence of the degree of respi-
ratory complex I impairment. Hum Mol Genet
23:1453–1466
Ishikawa K et al (2008) ROS-generating mitochondrial DNA
mutations can regulate tumor cell metastasis. Science
320:661–664
Janssen-Heininger YM et al (2008) Redox-based regulation of
signal transduction: principles, pitfalls, and promises. Free
Radic Biol Med 45:1–17
Jones JM et al (2003) Loss of Omi mitochondrial protease
activity causes the neuromuscular disorder of mnd2 mutant
mice. Nature 425:721–727
Ju YS et al (2014) Origins and functional consequences of
somatic mitochondrial DNA mutations in human cancer.
Elife 3:e02935
Kalhan SC, Hanson RW (2012) Resurgence of serine: an often
neglected but indispensable amino acid. J Biol Chem
287:19786–19791
Karlberg O, Canba¨ck B, Kurland CG, Andersson SG (2000) The
dual origin of the yeast mitochondrial proteome. Yeast
17:170–187
Kasamatsu H, Robberson DL, Vinograd J (1971) A novel
closed-circular mitochondrial DNA with properties of a
replicating intermediate. Proc Natl Acad Sci 68:2252–2257
Kaufman BA, Durisic N, Mativetsky JM, Costantino S, Han-
cock MA, Grutter P, Shoubridge EA (2007) The mito-
chondrial transcription factor TFAM coordinates the
assembly of multiple DNA molecules into nucleoid-like
structures. Mol Biol Cell 18:3225–3236
Kauppila TES, Kauppila JHK, Larsson NG (2017) Mammalian
mitochondria and aging: an update. Cell Metab 25:57–71
Kennedy SR, Salk JJ, Schmitt MW, Loeb LA (2013) Ultra-
sensitive sequencing reveals an age-related increase in
somatic mitochondrial mutations that are inconsistent with
oxidative damage. PLoS Genet 9:e1003794
Khan NA et al (2017) mTORC1 regulates mitochondrial inte-
grated stress response and mitochondrial myopathy pro-
gression. Cell Metab 26(419–428):e415
Kowald A, Kirkwood TBL (2000) Accumulation of defective
mitochondria through delayed degradation of damaged
123
Biogerontology
organelles and its possible role in the ageing of post-mitotic
and dividing cells. J Theor Biol 202:145–160
Kujoth GC et al (2005) Mitochondrial DNA mutations, oxida-
tive stress, and apoptosis in mammalian aging. Science
309:481–484
Kunkel M et al (2003) Overexpression of Glut-1 and increased
glucose metabolism in tumors are associated with a poor
prognosis in patients with oral squamous cell carcinoma.
Cancer 97:1015–1024
Labuschagne CF, Cheung EC, Blagih J, Domart MC, Vousden
KH (2019) Cell clustering promotes a metabolic switch
that supports metastatic colonization. Cell Metab
30:720–734
LeBleu VS et al (2014) PGC-1a mediates mitochondrial bio-
genesis and oxidative phosphorylation in cancer cells to
promote metastasis. Nat Cell Biol 16:992
Li H, Zhu H, Xu CJ, Yuan J (1998) Cleavage of BID by caspase
8 mediates the mitochondrial damage in the Fas pathway of
apoptosis. Cell 94:491–501
Li K et al (2000) Cytochrome c deficiency causes embryonic
lethality and attenuates stress-induced apoptosis. Cell
101:389–399
Lightowlers RN, Chinnery PF, Turnbull DM, Howell N (1997)
Mammalian mitochondrial genetics: heredity, hetero-
plasmy and disease. Trends Genet 13:450–455
Lin CC et al (2012) Loss of the respiratory enzyme citrate
synthase directly links the Warburg effect to tumor
malignancy. Sci Rep 2:785
Liu X, Kim CN, Yang J, Jemmerson R, Wang X (1996)
Induction of apoptotic program in cell-free extracts:
requirement for dATP and cytochrome c. Cell 86:147–157
Locasale JW et al (2011) Phosphoglycerate dehydrogenase
diverts glycolytic flux and contributes to oncogenesis. Nat
Genet 43:869–874
Logan A et al (2014) In vivo levels of mitochondrial hydrogen
peroxide increase with age in mtDNAmutator mice. Aging
Cell 13:765–768
Loschen G, Flohe´ L, Chance B (1971) Respiratory chain linked
H2O2 production in pigeon heart mitochondria. FEBS Lett
18:261–264
Lovell JF, Billen LP, Bindner S, Shamas-Din A, Fradin C, Leber
B, Andrews DW (2008) Membrane binding by tBid initi-
ates an ordered series of events culminating in membrane
permeabilization by Bax. Cell 135:1074–1084
Lu C et al (2012) IDH mutation impairs histone demethylation
and results in a block to cell differentiation. Nature
483:474–478
Luo X, Budihardjo I, Zou H, Slaughter C, Wang X (1998) Bid, a
Bcl2 interacting protein, mediates cytochrome c release
from mitochondria in response to activation of cell surface
death receptors. Cell 94:481–490
Maddocks OD, Berkers CR, Mason SM, Zheng L, Blyth K,
Gottlieb E, Vousden KH (2013) Serine starvation induces
stress and p53-dependent metabolic remodelling in cancer
cells. Nature 493:542–546
Maddocks ODK et al (2017) Modulating the therapeutic
response of tumours to dietary serine and glycine starva-
tion. Nature 544:372–376
Markham GD, Hafner E, Tabor CW, Tabor H (1980) S-adeno-
sylmethionine synthetase from Escherichia coli. J Biol
Chem 255:9082–9092
Mashimo T et al (2014) Acetate is a bioenergetic substrate for
human glioblastoma and brain metastases. Cell
159:1603–1614
McCord JM, Fridovich I (1969) Superoxide dismutase. An
enzymic function for erythrocuprein (hemocuprein). J Biol
Chem 244:6049–6055
McDonald SA et al (2008) Mechanisms of field cancerization in
the human stomach: the expansion and spread of mutated
gastric stem cells. Gastroenterology 134:500–510
Miquel J, Economos AC, Fleming J, Johnson JE Jr (1980)
Mitochondrial role in cell aging. Exp Gerontol 15:575–591
Mitchell P (1961) Coupling of phosphorylation to electron and
hydrogen transfer by a chemi-osmotic type of mechanism.
Nature 191:144–148
Mu¨nscher C, Rieger T, Mu¨ller-Ho¨cker J, Kadenbach B (1993)
The point mutation of mitochondrial DNA characteristic
for MERRF disease is found also in healthy people of
different ages. FEBS Lett 317:27–30
Nekhaeva E et al (2002) Clonally expanded mtDNA point
mutations are abundant in individual cells of human tis-
sues. Proc Natl Acad Sci 99:5521
Newman AC, Maddocks ODK (2017) One-carbon metabolism
in cancer. Br J Cancer 116:1499
Nieto MA, Huang RY, Jackson RA, Thiery JP (2016) EMT:
2016. Cell 166:21–45
Nikkanen J et al (2016) Mitochondrial DNA replication defects
disturb cellular dNTP pools and remodel one-carbon
metabolism. Cell Metab 23:635–648
Niu X, Trifunovic A, Larsson N-G, Canlon B (2007) Somatic
mtDNA mutations cause progressive hearing loss in the
mouse. Exp Cell Res 313:3924–3934
Noji H, Yasuda R, Yoshida M, Kinosita K (1997) Direct
observation of the rotation of F1-ATPase. Nature
386:299–302
Norddahl Gudmundur L et al (2011) Accumulating mitochon-
drial DNAMutations drive premature hematopoietic aging
phenotypes distinct from physiological stem cell aging.
Cell Stem Cell 8:499–510
Ojala D, Montoya J, Attardi G (1981) tRNA punctuation model
of RNA processing in human mitochondria. Nature
290:470–474
Parisi MA, Clayton DA (1991) Similarity of human mitochon-
drial transcription factor 1 to high mobility group proteins.
Science 252:965–969
Petros JA et al (2005) mtDNA mutations increase tumori-
genicity in prostate cancer. Proc Natl Acad Sci USA
102:719
Pfeiffer T, Schuster S, Bonhoeffer S (2001) Cooperation and
competition in the evolution of ATP-producing pathways.
Science 292:504–507
Piskounova E et al (2015) Oxidative stress inhibits distant
metastasis by human melanoma cells. Nature 527:186–191
Porporato PE et al (2014) A mitochondrial switch promotes
tumor metastasis. Cell Rep 8:754–766
Porporato PE, Filigheddu N, Pedro JMB-S, Kroemer G, Gal-
luzzi L (2017) Mitochondrial metabolism and cancer. Cell
Res 28:265
Pustylnikov S, Costabile F, Beghi S, Facciabene A (2018)
Targeting mitochondria in cancer: current concepts and
immunotherapy approaches. Transl Res 202:35–51
123
Biogerontology
Rosenzweig A, Blenis J, Gomes AP (2018) Beyond theWarburg
effect: how do cancer cells regulate one-carbon metabo-
lism? Front Cell Dev Biol. https://doi.org/10.3389/fcell.
2018.00090
Rossignol R, Malgat M,Mazat J-P, Letellier T (1999) Threshold
effect and tissue specificity: implication for mitochondrial
cytopathies. J Biol Chem 274:33426–33432
Sabharwal SS, Schumacker PT (2014) Mitochondrial ROS in
cancer: initiators, amplifiers or an Achilles’ heel? Nat Rev
Cancer 14:709–721
Salas A, Yao YG, Macaulay V, Vega A, Carracedo A, Bandelt
HJ (2005) A critical reassessment of the role of mito-
chondria in tumorigenesis. PLoS Med 2:e296
Sano S, Inoue S, Tanabe Y, Sumiya C, Koike S (1959) Signif-
icance of mitochondria for porphyrin and heme biosyn-
thesis. Science 129:275–276
Sarosiek KA, Letai A (2016) Directly targeting the mitochon-
drial pathway of apoptosis for cancer therapy using BH3
mimetics—recent successes, current challenges and future
promise. FEBS J 283:3523–3533
Satoh M, Kuroiwa T (1991) Organization of multiple nucleoids
and DNA molecules in mitochondria of a human cell. Exp
Cell Res 196:137–140
Sattler R, Tymianski M (2000) Molecular mechanisms of cal-
cium-dependent excitotoxicity. J Mol Med (Berlin, Ger-
many) 78:3–13
Schafer ZT et al (2009) Antioxidant and oncogene rescue of
metabolic defects caused by loss of matrix attachment.
Nature 461:109–113
Schlichtholz B, Turyn J, Goyke E, Biernacki M, Jaskiewicz K,
Sledzinski Z, Swierczynski J (2005) Enhanced citrate
synthase activity in human pancreatic cancer. Pancreas
30:99–104
SciaccoM, Bonilla E, Schon EA, DiMauro S,Moraes CT (1994)
Distribution of wild-type and common deletion forms of
mtDNA in normal and respiration-deficient muscle fibers
from patients with mitochondrial myopathy. Hum Mol
Genet 3:13–19
Sciacovelli M et al (2016) Fumarate is an epigenetic modifier
that elicits epithelial-to-mesenchymal transition. Nature
537:544–547
Shidara Y et al (2005) Positive contribution of pathogenic
mutations in the mitochondrial genome to the promotion of
cancer by prevention from apoptosis. Cancer Res
65:1655–1663
Shoubridge EA, Wai T (2007) Mitochondrial DNA and the
mammalian oocyte. Current topics in developmental biol-
ogy, vol 77. Academic Press, Cambridge, pp 87–111.
https://doi.org/10.1016/S0070-2153(06)77004-1
Singh KK, Desouki MM, Franklin RB, Costello LC (2006)
Mitochondrial aconitase and citrate metabolism in malig-
nant and nonmalignant human prostate tissues. Mol Cancer
5:14
Sonveaux P et al (2008) Targeting lactate-fueled respiration
selectively kills hypoxic tumor cells in mice. J Clin Invest
118:3930–3942
Stamp C et al (2018) Predominant asymmetrical stem cell fate
outcome limits the rate of niche succession in human
colonic crypts. EBioMedicine 31:166–173
Stewart JB, Chinnery PF (2015) The dynamics of mitochondrial
DNA heteroplasmy: implications for human health and
disease. Nat Rev Genet 16:530–542
Sugioka K, Nakano M, Totsune-Nakano H, Minakami H, Tero-
Kubota S, Ikegami Y (1988)Mechanism of O2- generation
in reduction and oxidation cycle of ubiquinones in a model
of mitochondrial electron transport systems. Biochim
Biophys Acta 936:377–385
Taylor RW, Turnbull DM (2005) Mitochondrial DNA muta-
tions in human disease. Nat Rev Genet 6:389–402
Taylor RW et al (2003)Mitochondrial DNAmutations in human
colonic crypt stem cells. J Clin Invest 112:1351–1360
Tomlinson IP et al (2002) Germline mutations in FH predispose
to dominantly inherited uterine fibroids, skin leiomyomata
and papillary renal cell cancer. Nat Genet 30:406–410
Trifunovic A et al (2004) Premature ageing in mice expressing
defective mitochondrial DNA polymerase. Nature
429:417–423
Tucker EJ et al (2011) Mutations in MTFMT underlie a human
disorder of formylation causing impaired mitochondrial
translation. Cell Metab 14:428–434
Turrens JF, Boveris A (1980) Generation of superoxide anion by
the NADH dehydrogenase of bovine heart mitochondria.
Biochem J 191:421–427
Wang C, Youle RJ (2009) The role of mitochondria in apoptosis.
Annu Rev Genet 43:95–118
Wang D, Kreutzer DA, Essigmann JM (1998) Mutagenicity and
repair of oxidative DNA damage: insights from studies
using defined lesions. Mutat. Res 400:99–115
Warburg O (1913) U¨ber sauerstoffatmende Ko¨rnchen aus
Leberzellen und u¨ber Sauerstoffatmung in Berkefeld-Fil-
traten wa¨ssriger Leberextrakte. Pflu¨ger’s Archiv fu¨r die
gesamte Physiologie des Menschen und der Tiere
154:599–617
Warburg O (1956a) On respiratory impairment in cancer cells.
Science 124:269–270
Warburg O (1956b) On the origin of cancer cells. Science
123:309–314
Warburg O, Wind F, Negelein E (1927) The metabolism of
tumours in the body. J Gen Physiol 8:519
Weinberg F et al (2010) Mitochondrial metabolism and ROS
generation are essential for Kras-mediated tumorigenicity.
Proc Natl Acad Sci USA 107:8788–8793
Weisiger RA, Fridovich I (1973) Superoxide dismutase: orga-
nelle specificity. J Biol Chem 248:3582–3592
Witkiewicz AK, Nguyen KH, Dasgupta A, Kennedy EP, Yeo
CJ, Lisanti MP, Brody JR (2008) Co-expression of fatty
acid synthase and caveolin-1 in pancreatic ductal adeno-
carcinoma: implications for tumor progression and clinical
outcome. Cell cycle (Georgetown, Tex) 7:3021–3025
Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle
RJ (1997) Movement of Bax from the cytosol to mito-
chondria during apoptosis. J Cell Biol 139:1281–1292
Youle RJ, Strasser A (2008) The BCL-2 protein family:
opposing activities that mediate cell death. Nat Rev Mol
Cell Biol 9:47
Zamzami N et al (1995) Sequential reduction of mitochondrial
transmembrane potential and generation of reactive oxy-




Zhang CF, Linnane AW, Nagley P (1993) Occurrence of a
particular base substitution (3243 A to G) in mitochondrial
DNA of tissues of ageing humans. Biochem Biophys Res
Commun 195:1104–1110
Zhang J et al (2003) Endonuclease G is required for early
embryogenesis and normal apoptosis in mice. Proc Natl
Acad Sci 100:15782
Zheng W, Khrapko K, Coller HA, Thilly WG, Copeland WC
(2006) Origins of human mitochondrial point mutations as
DNA polymerase c-mediated errors. Mutat Res 599:11–20
Zhou X, He L, Wu C, Zhang Y, Wu X, Yin Y (2017) Serine
alleviates oxidative stress via supporting glutathione synthesis
andmethionine cycle inmice.MolNutr FoodRes 61:1700262
Publisher’s Note Springer Nature remains neutral with
regard to jurisdictional claims in published maps and
institutional affiliations.
123
Biogerontology
